---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-047717"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:02:49.210685+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma appoints CBO Lucinda Warren as CFO effective Feb 9, 2026

## Summary
- Lucinda Warren, previously CBO, named Chief Financial & Business Officer; assumes principal financial/accounting officer duties.
- Warren had been CBO since Sept 2024; prior VP Business Development at Johnson & Johnson (2014-2024).
- No additional compensation or changes to her employment agreement for the CFO role.
- No family relationships with directors/officers; no reportable transactions under Item 404(a).

## SEC filing metadata
- accession: 0001193125-26-047717
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526047717/0001193125-26-047717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526047717/cue-20260209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-047717
- JSON: https://secwatch.observer/filing/0001193125-26-047717.json
- Plain text: https://secwatch.observer/filing/0001193125-26-047717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.